| Revenue growth | 3% YoY |
|---|---|
| Margins | Gross margin fell to 38.5% from 48% YoY |
| Demand visibility | Rural resilience but subdued urban consumption |
| Management confidence | Medium; focusing on volume growth amid inflation |
Growth
Revenue reached ₹773 Cr (+3%). Operating EBITDA fell 47.9% to ₹64.7 Cr. PAT dropped 50.8% to ₹47.6 Cr.
Outlook
Aiming for progressive margin recovery and volume-led growth; scaling new products like Exo Liquid and Maxo Incense Sticks.
Risks
Gross margins pressured by crude-linked input inflation and packaging cost volatility; subdued urban consumption trends noted.
Last quarter's promises, checked
Delivered
- Selective price hikes in March → visible in Q1 FY27 (= BEAT)
- Maintain volume growth focus → 5.3% volume growth (= BEAT)
- Scale Exo portfolio → Exo Bio-enzymatic Liquid launched (= BEAT)
Partly delivered
- FY27 to be stronger for Personal Care → Margo grew but overall margins crashed (= PARTIAL)
Missed
- Margins likely under pressure → Gross margin fell 950bps to 38.5% (= MISS)
- HI segment closer to profitability → EBITDA/PAT halved (= MISS)
Investor Presentation filed with BSE, NSE: JYOTHYLAB. Summary written with AI assistance from the document.
Jyothy Labs Ltd: key numbers
- Share price
- ₹191.07
- Market cap
- ₹7,016 Cr
- Revenue (annual)
- ₹2,944 Cr
- Net profit (annual)
- ₹333.2 Cr
- P/E (TTM)
- 24.7×Sector 43.4×
- Promoter holding
- 62.89%+0.00% QoQ
- FII holding
- 12.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jyothy Labs Ltd
All →Jyothy Labs Credit Rating
CARE Ratings has reaffirmed Jyothy Labs Limited's 'CARE AA; Stable' rating for its long-term bank facilities. The rating applies to facilities totaling Rs. 250 crore.
- Value
- ₹250.0 Cr
Jyothy Labs Employee Stock Options
Jyothy Labs has granted 1,46,141 Restricted Stock Units (RSUs) to eligible employees under its RSU Plan 2023. These units vest over a period of up to four years.
Jyothy Labs Capital Structure Change
Nalanda India Equity Fund Limited acquired a 0.85% stake in Jyothy Laboratories Limited. The acquisition of 3,102,384 shares increases the fund's total holding to 7.61%.
Jyothy Labs Other Announcement
Jyothy Labs has been assigned an ESG rating of '67' by NSE Sustainability Ratings & Analytics Limited. This rating was derived independently using public domain data.
Jyothy Labs Earnings Call Transcript: Key Takeaways
Management is firefighting severe gross margin contraction caused by extreme crude-oil linked inflation, relying on price hikes and channel expansion while facing aggressive competitive discounting.
- Call
- Guides 10% growth
Jyothy Labs Q1 FY27 Results: Net Profit ₹47.6 Cr, Down 50.8% YoY
Jyothy Labs Ltd reported revenue from operations of ₹773.4 Cr (+3.0% YoY) and net profit of ₹47.6 Cr (-50.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹47.6 Cr · -50.8% YoY